Clinical trial
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
NCT00101413 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00101413 |
|---|---|
| Title | BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) |
| Official title | A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma |
| Lead sponsor | Bayer, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Carcinoma, Non-Small Cell Lung |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) |
| Enrollment | 52 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Apr 1, 2008 |
| First posted | Jan 11, 2005 |
| Last update posted | Oct 30, 2013 |
| Countries | Germany, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: